Pancreatic Cancer Research

ResearcherUniversidade Federal de PernambucoActive in the last 2 years

Moacyr Jesus Barreto de Melo Rêgo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-1883-6012; OpenAlex author ID A5003939036, A5113293595, A5130968171. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
15
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 3 papers

Papers 10

  1. Interactions between the nervous system and PDAC progression: Regulatory mechanisms and therapeutic implications. Co-author DOI 10.1016/j.ejphar.2026.178829↗
  2. Label-free impedimetric biosensor based on lectin and polypyrrole film for the early detection of pancreatic cancer cells. Co-author DOI 10.1016/j.jpba.2025.117223↗
  3. Tumor cell-derived extracellular vesicles foster the immunosuppressive landscape of pancreatic cancer. Co-author DOI 10.1172/jci197733↗
  4. Multimodal Activity of a Novel Compound against Prostate and Pancreatic Cancer. Last author DOI 10.2174/0115680266351687250309020134↗
  5. 5-nitro-thiophene-thiosemicarbazone derivative induces cell death, cell cycle arrest, and phospho-kinase shutdown in pancreatic ductal adenocarcinoma cells. Last author DOI 10.1016/j.ejphar.2024.176963↗
  6. Macrophages reprogramming driven by cancer-associated fibroblasts under FOLFIRINOX treatment correlates with shorter survival in pancreatic cancer. Co-author DOI 10.1186/s12964-023-01388-7↗
  7. ANA-HEp2 pattern evaluation in pancreatic cancer: What can the autoantibodies tell us? Last author DOI 10.1016/j.hbpd.2022.02.006↗
  8. Galectin-12 in Pancreatic Cancer: A New Player in the Microenvironment? Last author DOI 10.1097/mpa.0000000000001909↗
  9. Galectin-3 is modulated in pancreatic cancer cells under hypoxia and nutrient deprivation. Last author DOI 10.1515/hsz-2019-0413↗
  10. Patients With Pancreatic Ductal Adenocarcinoma Have High Serum Galectin-9 Levels: A Sweet Molecule to Keep an Eye On. Last author DOI 10.1097/mpa.0000000000001126↗

Closest collaborators

The 15 strongest of 15 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michelle Melgarejo da Rosa · 3 shared papers, 2024–2026 · strength 0.87
  2. Joelson Germano Crispim · 2 shared papers, 2025–2026 · strength 0.66
  3. Amanda P.B. Albuquerque · 3 shared papers, 2021–2024 · strength 0.56
  4. Valécia de Cássia Mendonça da Costa · 2 shared papers, 2024–2026 · strength 0.52
  5. François Bertucci · 2 shared papers, 2024–2026 · strength 0.46
  6. Zainab Hussain · 2 shared papers, 2024–2026 · strength 0.46
  7. Richard Tomasini · 2 shared papers, 2024–2026 · strength 0.46
  8. Lília Vieira Galdino · 2 shared papers, 2021–2024 · strength 0.37
  9. Brenda Marques de Cerqueira · 1 shared paper, 2026 · strength 0.32
  10. Maria D.L. Oliveira · 1 shared paper, 2026 · strength 0.32
  11. Lucas B. Tavares · 2 shared papers, 2018–2020 · strength 0.24
  12. Antônio Felix da Silva Filho · 2 shared papers, 2018–2020 · strength 0.24
  13. Sophie Vasseur · 1 shared paper, 2026 · strength 0.24
  14. Flaviana Alves dos Santos · 1 shared paper, 2025 · strength 0.23
  15. Émilie Mamessier · 1 shared paper, 2024 · strength 0.22

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.